Yuji Yamamoto

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer · 2007 · 538 citations

Angiogenesis, Angiogenesis Inhibition, Tumor Growth +13

Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy

Shigeru Kinoshita, Noriko Koizumi, Morio Ueno et al. · New England Journal of Medicine · 2018 · 529 citations

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 478 citations · Full text

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase et al. · Cancer Letters · 2013 · 282 citations · Full text

Cancer Biology, Tumor Biology, Oncology +17

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Masako Ohno, Ichiro Yamaguchi, Itiro Yamamoto et al. · PubMed · 2000 · 255 citations

Tuberculosis Prevention, Pathology, Pharmacotherapy +19